All In Biotech

Drug Trial Radar · NCT07301034

A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack

Effects of Ziltivekimab Versus Placebo on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction. A Serial, Multivessel, Intravascular Ultrasound, Near-infrared Spectroscopy and Optical Coherence Tomography Imaging Study

Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 332 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

332

Planned (sponsor's estimate)

Start

Dec 18, 2025

Primary completion

Nov 14, 2028

Study completion Feb 24, 2029

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Dec 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is testing the effect of ziltivekimab on reducing plaque in the blood vessels of the heart, specifically aiming to manage or reduce atherosclerotic plaque. The purpose of the study is to determine whether ziltivekimab can effectively reduce this plaque. Participants will either receive ziltivekimab (the active medicine) or a placebo (a dummy medicine with no effect on the body), with the treatment assignment decided by chance. It is important to note that ziltivekimab is not yet approved in any country or region worldwide; therefore, it is a new medicine that doctors cannot prescribe. The study will last for about 15 months.

Conditions

  • Myocardial Infarction

Interventions

  • ZiltivekimabDrug

    Participants will receive ziltivekimab subcutaneously.

  • Ziltivekimab PlaceboDrug

    Participants will receive placebo matched to ziltivekimab subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in percent atheroma volume (PAV) as determined by greyscale intravascular ultrasound (IVUS) in matched regions of interestTime frame: From randomisation (week 0) to end-of-study (52-week)

Locations

20 sites in 6 countries. Site status is shown where the registry gives one.

  • Medizinische Universität Wien

    Vienna, Austria · Not yet recruiting

  • Aalborg Universitetshospital Hjertemedicinsk Afdeling

    Gistrup, Denmark · Not yet recruiting

  • Rigshospitalet - Kardiologisk Forskningsenhed

    København Ø, Denmark · Not yet recruiting

  • Ospedale Policlinico San Martino

    Genova, Italy · Not yet recruiting

  • AOU Maggiore della Carità di Novara - Dipartimento Toraco-Cardio-Vascolare - SCDU Cardiologia

    Novara, Italy · Not yet recruiting

  • Azienda Ospedaliera Universitaria San Luigi Gonzaga - S.C.D.O. Microcitemie e malattie rare ematologiche

    Orbassano, Italy · Not yet recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCS

    Rome, Italy · Not yet recruiting

  • IRCCS Policlinico San Donato

    San Donato Milanese, Italy · Not yet recruiting

  • Azienda Ospedaliera San Giovanni Addolorata

    Rome, Lazio, Italy · Not yet recruiting

  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII

    Bergamo, Lombardy, Italy · Not yet recruiting

  • DAI Scienze Mediche - UOC Endocrinologia

    Messina, Sicily, Italy · Not yet recruiting

  • Presidio Ospedaliero di Rivoli

    Rivoli, To, Italy · Not yet recruiting

  • Radboudumc

    Nijmegen, Netherlands · Not yet recruiting

  • Erasmus MC

    Rotterdam, Netherlands · Not yet recruiting

  • Hospital Universitario de la Princesa

    Madrid, Spain · Not yet recruiting

  • Hospital Universitario Marqués de Valdecilla

    Santander, Spain · Not yet recruiting

  • Universitäres Herzzentrum

    Basel, Switzerland · Recruiting

  • Inselspital-Universitätsklinik für Kardiologie

    Bern, Switzerland · Recruiting

  • HUG-Service de Cardiologie

    Geneva, Switzerland · Not yet recruiting

  • LUKS-Herzzentrum

    Lucerne, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.